Related Experiment Video
Updated: Aug 24, 2026
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Emerging therapies for angina: new modalities may offer additional clinical options
1Stanford University School of Medicine, Falk Cardiovascular Research Center, Stanford, California 94305, USA. hf.cxv@forsythe.stanford.edu
Insights
New metabolic modulators offer a promising, well-tolerated treatment for chronic angina when other therapies fail. These novel antianginal drugs effectively reduce chest pain episodes and improve exercise capacity in patients with coronary artery disease.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic angina and coronary artery disease impose significant social and economic burdens.
- Existing treatments for chronic angina are often ineffective, contraindicated, or too risky/costly for many patients.
Purpose of the Study:
- To introduce a new class of antianginal drugs, metabolic modulators, as a potential therapeutic option.
- To evaluate the efficacy and tolerability of metabolic modulators in patients with chronic angina.
Main Methods:
- Controlled clinical trials were conducted to assess the impact of metabolic modulators.
- Key outcomes measured included angina episode frequency and exercise duration.
Main Results:
- Metabolic modulators demonstrated significant reductions in the frequency of angina episodes.
- Patients treated with these agents showed an increased duration of exercise sessions.
- The new drug class was found to be well tolerated by study participants.
Conclusions:
- Metabolic modulators represent a promising new therapeutic avenue for managing chronic angina.
- These drugs offer an effective and safe alternative for patients with limited options.
- Further evaluation and availability of metabolic modulators could alleviate the burden of chronic angina.
Abstract:
The social and economic burdens of chronic angina are enormous, and the morbidity and mortality associated with its underlying cause, coronary artery disease, are high. For many patients with chronic angina, current drug therapies are contraindicated or ineffective, and surgical procedures too risky or costly. Most newer approaches have not yet been sufficiently evaluated and can be expensive, time-consuming, or both. A new class of antianginal drugs, the metabolic modulators, will soon be available. In controlled clinical trials, these agents have shown promising results in reducing the frequency of angina episodes and lengthening the duration of exercise sessions. They are also well tolerated.
Related Concept Videos
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:29Angina III: Clinical Manifestations and Assessment
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...